Diabetes mellitus during olanzapine and quetiapine treatment in Japan.
Cohen
Dan
D
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D000075202:Contraindications; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D003937:Diagnosis, Differential; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D000069348:Quetiapine Fumarate; D012107:Research Design / Q000592:standards; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D000077152:Olanzapine